LM11A-31 dihydrochloride

Name: LM11A-31 dihydrochloride
Brand: MedChemExpress
SKU: HY-110155
Rating: 5.0 (7 reviews)

Cat. No.: HY-110155 Purity: ≥98.0%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

LM11A-31 dihydrochloride, a non-peptide p75^NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist. LM11A-31 dihydrochloride is an amino acid derivative with high blood-brain barrier permeability and blocks p75-mediated cell death. LM11A-31 dihydrochloride reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression.

For research use only. We do not sell to patients.

LM11A-31 dihydrochloride Chemical Structure

CAS No. : 1243259-19-9

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in Water ready for reconstitution	USD 61	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in Water	USD 61	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 55	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 81	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 182	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 270	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 495	In-stock	Estimated Time of Arrival: December 31
500 mg	USD 1500	In-stock	Estimated Time of Arrival: December 31
1 g		Get quote
5 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 7 publication(s) in Google Scholar

Other Forms of LM11A-31 dihydrochloride:

(Rac)-LM11A-31 dihydrochloride Get quote
LM11A-31 Get quote

7 Publications Citing Use of MCE LM11A-31 dihydrochloride

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Neurotensin Receptor Isoform Specific Products:

View All Isoforms

NTR1 NTR2

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

proNGF^[1]

In Vivo

LM11A-31 (oral gavage; 50 mg kg/day for 4 weeks) significantly mitigates proNGF accumulation and preserves BRB integrity^[1].
LM11A-31 (orally; 50 or 75 mg/kg) administered for 3 months starting at 6-8 months of age prevents and/or reverses atrophy of basal forebrain cholinergic neurites and cortical dystrophic neurites in mid-stage male APPL/S mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6 J mice^[1]
Dosage:	50 mg kg/day
Administration:	Oral gavage; for 4 weeks
Result:	Mitigated proNGF accumulation and preserved BRB integrity.

Molecular Weight

316.27

Formula

C₁₂H₂₇Cl₂N₃O₂

CAS No.

1243259-19-9

Appearance

Solid

Color

White to off-white

SMILES

CC[C@H](C)[C@H](N)C(NCCN1CCOCC1)=O.Cl.Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, stored under nitrogen, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : 100 mg/mL (316.19 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.1619 mL	15.8093 mL	31.6186 mL
5 mM	0.6324 mL	3.1619 mL	6.3237 mL
10 mM	0.3162 mL	1.5809 mL	3.1619 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 100 mg/mL (316.19 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: ≥98.0%

Select Batch:

Data Sheet (273 KB) SDS (252 KB)

COA (246 KB) HNMR (188 KB)

Handling Instructions (2659 KB)

References

[1]. Elshaer SL, et al. Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinalvascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway. Diabetologia. 2019 Aug;62(8):1488-1500. [Content Brief]

[2]. Simmons DA, et al. A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression. PLoS One. 2014 Aug 25;9(8):e102136. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O	1 mM	3.1619 mL	15.8093 mL	31.6186 mL	79.0464 mL
	5 mM	0.6324 mL	3.1619 mL	6.3237 mL	15.8093 mL
	10 mM	0.3162 mL	1.5809 mL	3.1619 mL	7.9046 mL
	15 mM	0.2108 mL	1.0540 mL	2.1079 mL	5.2698 mL
	20 mM	0.1581 mL	0.7905 mL	1.5809 mL	3.9523 mL
	25 mM	0.1265 mL	0.6324 mL	1.2647 mL	3.1619 mL
	30 mM	0.1054 mL	0.5270 mL	1.0540 mL	2.6349 mL
	40 mM	0.0790 mL	0.3952 mL	0.7905 mL	1.9762 mL
	50 mM	0.0632 mL	0.3162 mL	0.6324 mL	1.5809 mL
	60 mM	0.0527 mL	0.2635 mL	0.5270 mL	1.3174 mL
	80 mM	0.0395 mL	0.1976 mL	0.3952 mL	0.9881 mL
	100 mM	0.0316 mL	0.1581 mL	0.3162 mL	0.7905 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.